J

Examining Triplet Therapy in MM: Analysis of ELOQUENT-3 and MAIA Trials

By Joshua Richter 2 Videos
July 20, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

26:48
Bristol Myers Squibb Hematology

Expert Discusses Data for a RRMM Regimen

Feat. K. Shain

Related Content

AUTOPLAY
SOHO 3rd Italian Conference

SOHO 3rd Italian Conference

Mon, Sep 27, 2021
17:59
Parameswaran Hari

Delivering the Best Initial Treatment for Myeloma: Induction Therapy and R…

10:37
Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Management of Multiple Myeloma: Smoldering Disease, Induction Therapy in T…

Feat. K. Shain
09:20
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Curative Strategy for High-Risk Smoldering Myeloma, Consolidation Therapy …

Feat. A. Rosko
14:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patients Can …

Feat. T. Martin
05:09
Association of Community Cancer Centers (ACCC)

72 y/o Woman With IgG Lambda High-Risk Multiple Myeloma (del17p): Disease …

Feat. K. Maples
25:24
Extracellular Vesicles and Their Role in Patients With Multiple Myeloma

Biologically Based Therapies for MM: Surveying Novel Options

Feat. K. Anderson
26:18
Morie Gertz

Treatment of Relapsed Myeloma: Overview of Approved Drugs & Optimal Se…

08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
16:22
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

SOHO Debate: Frontline Therapy for Fit MM Patients Should Include an Antib…

Feat. P. Voorhees
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
06:31
2nd SOHO Italian Conference

Treatment Options for the R/R MM Patients: A Review of the Current Data

Feat. K. Anderson
12:53
2nd SOHO Italian Conference

Genetic Profiling in MM: Can Genomics Help With High-Risk Disease? How Can…

Feat. N. Bolli
23:44
UAB Hematology Review 2021

Therapeutic Options for R/R MM: Single Agent vs. Doublets vs. Triplets, Su…

Feat. K. Godby
18:43
7th Eurasian Hematology Oncology Summit

2020 Updates on CAR-T in R/R MM: What Is the Incidence of AEs With bb2121?…

Feat. E. Terpos
13:27
Shaji Kumar

Evolving Concepts in the Diagnosis and Risk Stratification of Myeloma

14:57
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on HDT in Frontline MM: Is Lenalidomide, Bortezomib, …

Feat. A. Nooka
05:33
Baptist Health South Florida CME

2021 Advancements in Blood Cancers: Blinatumomab in ALL, Pre-ASCT Inductio…

Feat. G. Koehne
12:16
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/Refract…

Feat. M. Dimopoulos
09:50
Nina Shah

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Mainten…

09:00
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Treatment Options in R/R Multiple Myeloma: Tips for Selecting Among the My…

Feat. J. Berdeja